Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016 Jul 7:16:405.
doi: 10.1186/s12885-016-2431-x.

A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model

Emeka I Udeh  1 , Chimaobi G Ofoha  2 , David A Adewole  3 , Ikenna I Nnabugwu  4
Affiliations
Comparative Study

A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model

Emeka I Udeh et al. BMC Cancer. .

Abstract

Background: The number of Nigerian men presenting with benign prostatic hyperplasia is on the rise because of increase awareness about the ailment. With the renewed effort by the national health insurance scheme to cover the informal sector, it becomes imperative to determine the cost implication for managing Benign Prostatic Hyperplasia (BPH) and the cost effective drug combination to be adopted. The objective of this study is to estimate cost effective analysis (CEA) of fixed -dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy from the health service provider perspective design.

Methods: An interactive Markov's model was used to generate incremental cost per QALY and incremental cost per life years gained. 2.9 million Men who were 50 years of age were fed into the model. The outcome measures included: costs of drug treatment, consultation, acute urinary retention (AUR), transurethral resection of prostate (TURP), hospitalisation post TURP, and quality adjusted life years (QALYs), incremental cost per life years gained, and incremental cost per QALY gained.

Results: Fixed-dose combination of dutasteride and tamsulosin (FDCT) produced an Incremental cost-effectiveness ratios of US$1481.92 per Quality adjusted for life-years saved.

Conclusion: Universal FDCT provision for Nigeria has major economic implications. This study in the context of its limitations has demonstrated the cost effectiveness of FDCT for the long term treatment of patients with moderate to severe BPH from the perspective of a developing country. Currently, there are few studies available to give economic data evidence to policy makers in Nigeria which is applicable to developing countries with similar economies. As such, the findings in this study will be relevant to policy makers in these countries.

Keywords: Benign prostatic hyperplasia; Cost effectiveness analysis; Dutasteride monotherapy; Fixed dose combination of dutasteride- tamsulosin; Nigerian men.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Illustrative Markov model showing discrete health states and direction of transitions (arrows)
Fig. 2
Fig. 2
Graphical representation of the deterministic sensitivity analysis result; depicting effects of parameters on baseline ICER
Fig. 3
Fig. 3
Cost effectiveness plane showing the plots of ICERs generated from simulation
Fig. 4
Fig. 4
Cost- effectiveness acceptability curve for fixed dose combination therapy versus dutasteride
See this image and copyright information in PMC

References

    1. Desgrandchamps F, de la Taille A, Azzouzi A-R, Fourmarier M, Haillot O, Lukacs B, Saussine C, d’Urologie CdTMdlHdlAF Management of non-complicated BPH: proposition of a renewed decision tree. World J Urol. 2006;24(4):367–370. doi: 10.1007/s00345-006-0096-9. - DOI - PubMed
    1. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines) Eur Urol. 2004;46(5):547–554. doi: 10.1016/j.eururo.2004.07.016. - DOI - PubMed
    1. Speakman M, Kirby R, Joyce A, Abrams P, Pocock R. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int. 2004;93(7):985–990. doi: 10.1111/j.1464-410X.2004.04765.x. - DOI - PubMed
    1. Ezeanyika LU, Ejike CE, Obidoa O, Elom SO. Prostate disorders in an apparently normal Nigerian population 1: Prevalence. Biokemistri. 2006;18(2):127–132.
    1. National Population Commision. Population Distribution By Age, Sex and Marital Status Table. 2006. http://www.population.gov.ng.

Publication types

MeSH terms